TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21306085

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri supplementation (containing L. reuteri, ATCC 55730 and ATCC PTA 5289) for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 23
Study: 17437874

Group type: EXPERIMENTAL
Intervention: 10% propolis solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20% propolis solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-shelf life light milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hank's Balanced Salt Solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tap water (negative control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DMEM (positive control)
Number of subjects: 0
Study: 15820998

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 864

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 864
Study: 11434589

Group type: EXPERIMENTAL
Intervention: Oral PEG 4000 treatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intraluminal instillation of PEG 4000
Number of subjects: 12
Study: 9757919

Group type: EXPERIMENTAL
Intervention: pHi-guided therapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control
Number of subjects: 55
Study: 8141282

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) during insulin clamp
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control study (no LBNP) during insulin clamp
Number of subjects: 7
Study: 3202416

Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30260780

Group type: EXPERIMENTAL
Intervention: Music therapy added to sedation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No music treatment (control group)
Number of subjects: 0
Study: 27790965

Group type: EXPERIMENTAL
Intervention: Practice cochlear implant surgery on different specimens for four weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Practice cochlear implant surgery on the same specimen for four weeks
Number of subjects: 11
Study: 26574755

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (SB) 0.3 g∙kg‐1BM
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 15
Study: 23519431

Group type: EXPERIMENTAL
Intervention: Increased number of trajectory changes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spatial proximity controlled
Number of subjects: 0
Study: 20595158

Group type: EXPERIMENTAL
Intervention: CPAP treatment with heated humidification
Number of subjects: 20

Group type: COMPARATOR
Intervention: CPAP treatment with sham‐heated humidification
Number of subjects: 20
Study: 18294230

Group type: EXPERIMENTAL
Intervention: Glycine powder air-polishing (GPAP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sodium bicarbonate air-polishing (SBAP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hand-instrumentation
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 10
Study: 16542188

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 227

Group type: COMPARATOR
Intervention: Lamotrigine vs Placebo
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Lamotrigine vs Lithium
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Lamotrigine and Lithium
Number of subjects: 227
Study: 12667663

Group type: EXPERIMENTAL
Intervention: IFN-beta 1a therapy
Number of subjects: 127
Study: 10738212

Group type: EXPERIMENTAL
Intervention: HAI group (5‐fluorouracil (5‐FU) 500 mg/day for 4 days followed by a 3‐day rest, continued for 6 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: HAI group
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 9433595

Group type: EXPERIMENTAL
Intervention: Sib-pair analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Association studies
Number of subjects: 0
Study: 8497668

Group type: COMPARATOR
Intervention: Procedural intervention
Number of subjects: 301

Group type: COMPARATOR
Intervention: Procedural/Belief intervention
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 301

Group type: COMPARATOR
Intervention: Belief intervention
Number of subjects: 301
Study: 3303926

Group type: EXPERIMENTAL
Intervention: Amphotericin B plus flucytosine (0.3 mg/kg per day of amphotericin B and 150 mg/kg per day of flucytosine) for four weeks
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Amphotericin B plus flucytosine (0.3 mg/kg per day of amphotericin B and 150 mg/kg per day of flucytosine) for six weeks
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Flucytosine toxicity
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Toxic reactions contributing to death
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Monitoring recommendations
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Flucytosine initial dosing recommendations
Number of subjects: 194
Study: 31050312

Group type: EXPERIMENTAL
Intervention: Daily footbath with alkaline soap
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Daily footbath with acidic soap
Number of subjects: 97

Group type: COMPARATOR
Intervention: Simple bandage of gauze dressing
Number of subjects: 97
Study: 28842722

Group type: EXPERIMENTAL
Intervention: Interval walking training (IWT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Continuous walking training (CWT)
Number of subjects: 14
Study: 25112383

Group type: EXPERIMENTAL
Intervention: Surgical technique or mesh type for primary inguinal hernia repair (exact details not specified)
Number of subjects: 10810

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROMs)
Number of subjects: 10810

Group type: COMPARATOR
Intervention: Meta-analyses
Number of subjects: 10810
Study: 21631599

Group type: EXPERIMENTAL
Intervention: Block-periodized multipurpose exercise program (EG, n=43)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Wellness-control program (CG, n=42)
Number of subjects: 85
Study: 20659181

Group type: EXPERIMENTAL
Intervention: Phosphoric acid + opaque sealant (group I)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond + opaque sealant (group II)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Phosphoric acid + clear sealant (group III)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond + clear sealant (group IV)
Number of subjects: 80
Study: 19761688

Group type: EXPERIMENTAL
Intervention: Proximal femoral nail antirotation (PFNA)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 121
Study: 17157802

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (80 mg zinc oxide, 2 mg cupric oxide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14962830

Group type: EXPERIMENTAL
Intervention: Ascorbic acid infusion
Number of subjects: 15
Study: 12361201

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol (100 microg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9825752

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 70

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 70
Study: 8109546

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 53
Study: 2572652

Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ranitidine, 300 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydroxyzine plus ranitidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 53172

Group type: EXPERIMENTAL
Intervention: Highly dosed organo-heparinoid ointment and gel
Number of subjects: 513
Study: 434431

Group type: EXPERIMENTAL
Intervention: R 33812 4 mg i.v. before anaesthesia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: R 33812 8 mg i.v. before anaesthesia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: R 33812 10 mg orally with premedication
Number of subjects: 150

Group type: COMPARATOR
Intervention: Diazepam 10 mg orally as premedication
Number of subjects: 150
Study: 31253091

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1773

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 1773

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1773
Study: 28209505

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conservative treatments plus gabapentin (group GPN)
Number of subjects: 50
Study: 25596096

Group type: EXPERIMENTAL
Intervention: Probiotic (Bifidobacterium lactis)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Synbiotic (Bifidobacterium lactis plus inulin)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Prebiotic (inulin)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Probiotics, prebiotics, or synbiotic
Number of subjects: 400
Study: 23798746

Group type: EXPERIMENTAL
Intervention: DOWN - 45 minutes of physical therapy + 30 minutes of treadmill with 5% descending slope
Number of subjects: 38

Group type: COMPARATOR
Intervention: UP - 45 minutes of physical therapy + 30 minutes of treadmill with 5% ascending slope
Number of subjects: 38
Study: 21840602

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant
Number of subjects: 255

Group type: COMPARATOR
Intervention: Systemic corticosteroids plus immunosuppression
Number of subjects: 255
Study: 19482895

Group type: EXPERIMENTAL
Intervention: Progressive group (n = 7)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Traditional group (n = 7)
Number of subjects: 16
Study: 17503973

Group type: EXPERIMENTAL
Intervention: Guided discontinuation strategy
Number of subjects: 131

Group type: COMPARATOR
Intervention: Maintenance treatment
Number of subjects: 131
Study: 15194574

Group type: EXPERIMENTAL
Intervention: Prednisolone 7 mg/day
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 12077577

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE(2)) applied intradermally (10(‐8)‐10(‐4) M)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 16
Study: 9466515

Group type: EXPERIMENTAL
Intervention: Priming with recombinant vaccinia gp160LAI and boosting with recombinant gp120SF-2, gp120LAI, gp120MN, or gp160MN
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Boosting with gp120
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Vaccination regimen with vac/env and gp120
Number of subjects: 56
Study: 7621570

Group type: EXPERIMENTAL
Intervention: Nocturnal infusion of octreotide (1-1.5 micrograms/kg body weight, subcutaneously)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nocturnal infusion of octreotide
Number of subjects: 9
Study: 2496951

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (L‐NOG) 0.75 mg administered orally for 4 days during the periovulatory period (days 9, 11, 13, and 15)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (L‐NOG) 0.75 mg administered orally for 4 days during the periovulatory period (days 11, 12, 16, and 19)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (L‐NOG) 0.75 mg administered orally during the follicular or luteal phase
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (L‐NOG) 0.75 mg administered orally during the follicular phase
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (L‐NOG) administered during treatment
Number of subjects: 72
Study: 1264926

Group type: EXPERIMENTAL
Intervention: Aspirin B.P. 300 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Claradin 150 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aspirin B.P. 75 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Aloxiprin 300 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Claradin 50 mg daily for 12-15 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Claradin 25 mg daily
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: All preparations
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment
Number of subjects: 17
Study: 31902567

Group type: EXPERIMENTAL
Intervention: iTBS (intermittent theta burst stimulation) over the DLPFC for four weeks (20 daily sessions, 900 pulses per day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sham stimulation over the DLPFC
Number of subjects: 126
Study: 30808379

Group type: EXPERIMENTAL
Intervention: mHealth intervention (initial SMS alert and reminders)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: mHealth intervention (follow-up email and SMS for non-adherents)
Number of subjects: 200
Study: 28820793

Group type: EXPERIMENTAL
Intervention: Codeine (30 mg) plus acetaminophen (500 mg) orally 4 times per day for 4 days after PRK
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26253644

Group type: EXPERIMENTAL
Intervention: Internet-delivered acceptance and commitment therapy (iACT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 39
Study: 23652245

Group type: EXPERIMENTAL
Intervention: RA MU-Optimized plans
Number of subjects: 7

Group type: COMPARATOR
Intervention: RA Clinical plans
Number of subjects: 7
Study: 22115211

Group type: EXPERIMENTAL
Intervention: R2 sympathicotomy
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: R3 sympathicotomy
Number of subjects: 121
Study: 19278731

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg Zn/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imipramine (approximately 140 mg/day) + Zinc supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Imipramine (approximately 140 mg/day) + Placebo
Number of subjects: 60
Study: 16374651

Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 143

Group type: COMPARATOR
Intervention: Total hip replacement (THR)
Number of subjects: 143
Study: 15290454

Group type: EXPERIMENTAL
Intervention: Long-term low-dose daily 14-membered-ring macrolide therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no macrolide therapy)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chemosensitivity testing on H. pylori strains
Number of subjects: 90
Study: 12184425

Group type: EXPERIMENTAL
Intervention: Ketac‐Endo (KE), without smear layer (smear ‐)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ketac‐Endo (KE), with smear layer (smear +)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: AH 26, smear (‐)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: AH 26, smear (+)
Number of subjects: 72

Group type: COMPARATOR
Intervention: nonprepared (negative control)
Number of subjects: 72

Group type: COMPARATOR
Intervention: prepared but unfilled (positive control)
Number of subjects: 72
Study: 9519356

Group type: EXPERIMENTAL
Intervention: Combination of LHRH agonist buserelin (nasal spray) and cyproterone acetate (Androcur), either continuously or for the first 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 0
Study: 8128920

Group type: EXPERIMENTAL
Intervention: Lentinan (2 mg weekly for inpatients and 4 mg every other week for outpatients)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (no Lentinan)
Number of subjects: 69
Study: 2475954

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine (5 mg/kg body-weight infused over 30 minutes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isotonic saline (same volume as lignocaine)
Number of subjects: 10
Study: 1020050

Group type: EXPERIMENTAL
Intervention: Combination of adriamycin, vincristine and methotrexate (AVM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combination of vinblastine, bleomycin and mithramycin (VBM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AVM
Number of subjects: 24

Group type: COMPARATOR
Intervention: VBM
Number of subjects: 24
Study: 31628359

Group type: EXPERIMENTAL
Intervention: Manual infusion (MI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pump infusion (PI)
Number of subjects: 100
Study: 28640480

Group type: EXPERIMENTAL
Intervention: Involvement of ex-offender service user consultants in research
Number of subjects: 4
Study: 28404199

Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral mesh rectopexy (n=38)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Laparoscopic posterior sutured rectopexy (n=37)
Number of subjects: 75
Study: 24564746

Group type: EXPERIMENTAL
Intervention: Maternal positioning techniques
Number of subjects: 438

Group type: COMPARATOR
Intervention: Usual care (expectant management)
Number of subjects: 438
Study: 21673620

Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty (BRYAN prosthesis)
Number of subjects: 120

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 120
Study: 19874444

Group type: EXPERIMENTAL
Intervention: Buffered esomeprazole (BE) 40 mg twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous pantoprazole 40 mg bolus
Number of subjects: 10
Study: 17551145

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 2968

Group type: COMPARATOR
Intervention: Carboplatin-based chemotherapy
Number of subjects: 2968

Group type: COMPARATOR
Intervention: Carboplatin-based chemotherapy in patients with nonsquamous tumors
Number of subjects: 2968

Group type: COMPARATOR
Intervention: Carboplatin-based chemotherapy in patients treated with third-generation chemotherapy
Number of subjects: 2968
Study: 16376772

Group type: EXPERIMENTAL
Intervention: Bicuspid AS group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Tricuspid AS group
Number of subjects: 53
Study: 12214931

Group type: EXPERIMENTAL
Intervention: 2.5% ethanolamine oleate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5% ethanolamine oleate
Number of subjects: 40
Study: 10088798

Group type: EXPERIMENTAL
Intervention: C-test (constant-load treadmill test, 3 km/hr; fixed grade of 12%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G-test (graded-exercise treadmill test, 3 km/hr; increase in grade of 3.5% every 3 minutes)
Number of subjects: 50
Study: 7585843

Group type: EXPERIMENTAL
Intervention: augmented betamethasone dipropionate 0.05% lotion
Number of subjects: 197

Group type: COMPARATOR
Intervention: clobetasol propionate 0.05% solution
Number of subjects: 197
Study: 2209315

Group type: EXPERIMENTAL
Intervention: MaxEPA (10 g/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 80
Study: 6996928

Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg tablets, 4 times daily)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 31244434

Group type: EXPERIMENTAL
Intervention: Co-ultraPEALut (1 mg/kg o.s.) administered 1h before LPS injection or 1h and 6h after LPS injection or 1h before LPS injection and 1h and 6h after LPS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glialia® (700 mg PEA + 70 mg luteolin)
Number of subjects: 0
Study: 28728956

Group type: EXPERIMENTAL
Intervention: Ataluren (40 mg/kg per day, orally, three times daily)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Ataluren (40 mg/kg per day)
Number of subjects: 230
Study: 26056125

Group type: EXPERIMENTAL
Intervention: 15 mg pSDF-1
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 30 mg pSDF-1
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 25230350

Group type: EXPERIMENTAL
Intervention: diclofenac (0.1%)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: pranoprofen (0.1%)
Number of subjects: 239

Group type: COMPARATOR
Intervention: control, physiological normal saline solution
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: diclofenac (0.1%) and epinephrine
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: pranoprofen (0.1%) and epinephrine
Number of subjects: 239

Group type: COMPARATOR
Intervention: control, physiological normal saline and epinephrine solutions
Number of subjects: 239
Study: 22559159

Group type: EXPERIMENTAL
Intervention: Exercise therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise therapy + Amlodipine (calcium channel blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise therapy + Valsartan (angiotensin receptor blocker)
Number of subjects: 0
Study: 19712037

Group type: EXPERIMENTAL
Intervention: Zoster vaccine
Number of subjects: 981

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: Zoster vaccine and HZ
Number of subjects: 981
Study: 17726086

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (200 mg im every other week for 90 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (sesame oil vehicle im)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Number of subjects: 15
Study: 15894768

Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12503776

Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg/day
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day
Number of subjects: 110

Group type: COMPARATOR
Intervention: Octa-60 5 mg/day
Number of subjects: 110

Group type: COMPARATOR
Intervention: Octa-60 10 mg/day
Number of subjects: 110
Study: 9583201

Group type: EXPERIMENTAL
Intervention: Glycated Hemoglobin (GHb)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fructosamine (Frc)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fasting Blood Glucose (FBG)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Initial White Blood Cell (WBC) count
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hyperglycemia during induction therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Family history of diabetes mellitus
Number of subjects: 26
Study: 7535267

Group type: EXPERIMENTAL
Intervention: Process-oriented treatment (POR chi) approach
Number of subjects: 75

Group type: COMPARATOR
Intervention: Traditional or general motor approach
Number of subjects: 75

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 75